Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-DPP4/CD26 Antibody (6M894) is a Mouse antibody targeting DPP4/CD26. Anti-DPP4/CD26 Antibody (6M894) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $198 | 7-10 days |
Description | Anti-DPP4/CD26 Antibody (6M894) is a Mouse antibody targeting DPP4/CD26. Anti-DPP4/CD26 Antibody (6M894) can be used in FCM. |
Alias | dipeptidylpeptidase 4 |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 6M894 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human CD26(DPP4) expression on human whole blood lymphocytes. Cells were stained with purified anti-Human CD26(DPP4), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
Application | FCM |
Recommended Dose | FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human DPP4 / CD26 (rh DPP4 / CD26; TMPY-00779; NP_001926.2; Asn29-Pro766). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes. |
Conjucates | Unconjugated |
Others Formats | APC/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human DPP4 / CD26 Protein (TMPY-00779) |
Antigen Species | Human |
Biology Area | Serine Proteases and Regulators |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.